Production started for Lu-177 ready to use doses

We have commenced production of Lu-177 ready-to-use doses, marking a significant milestone in our commitment to advancing nuclear medicine solutions. Lu-177, a therapeutic radionuclide, holds immense promise in the treatment of various cancers, particularly neuroendocrine tumors and prostate cancer.

The production of Lu-177 ready-to-use doses underscores Monrol’s dedication to meeting the growing demand for innovative cancer therapies in the region and beyond. Leveraging state-of-the-art production facilities and adhering to stringent quality control measures, Monrol ensures the highest standards of safety, efficacy, and reliability in every dose produced.